Choose your country to see the products for your location

P044 NF2

SALSA MLPA Probemix P044 NF2 detects copy number variations in the NF2 gene.

Specifications

Contents: 43 MLPA probes, including 21 probes for NF2, 5 probes for genes upstream of NF2, and 4 probes for genes downstream of NF2.

Tissue: genomic DNA isolated from human peripheral whole blood. Research use: genomic DNA from FFPE or fresh tumour tissue.

Application: NF2-related schwannomatosis.

IVDR certified for in vitro diagnostic (IVD) use.

Quick links

List Prices Documentation

Key related products

D002 Hereditary Cancer Panel 2

Targets 56 genes involved in hereditary predisposition to cancer, including NF2.

P081 NF1 mix 1

Targets NF1, associated with neurofibromatosis type I (NF1).

P082 NF1 mix 2

Targets NF1, associated with neurofibromatosis type I (NF1).

View all

This product has recently been CE-marked for in vitro diagnostic (IVD) use under the In Vitro Diagnostic Regulation (IVDR; EU 2017/746), which replaces the former CE-marking under the IVD Directive (IVDD; Directive 98/79/EC).

A new version of the P044 probemix has been released in June 2026. The previous version (P044-C1) can still be ordered until December 2026. Please indicate the product version of your choice when ordering. If no product version is mentioned, the latest (D1) version will be shipped.

Intended purpose

The SALSA MLPA Probemix P044 NF2 is an in vitro diagnostic (IVD) or research use only (RUO) semi-quantitative manual assay for the detection of deletions or duplications in the NF2 gene in genomic DNA isolated from human peripheral whole blood specimens. P044 NF2 is intended to confirm a potential cause for, and clinical diagnosis of, NF2-related schwannomatosis, and for molecular genetic testing of at-risk family members. NF2-related schwannomatosis has a high incidence of mosaicism, and mosaic mutations may not be detectable in blood.

For the full intended purpose, see the product description.

Clinical background

NF2-related schwannomatosis (formerly known as Neurofibromatosis type 2) is an autosomal dominant syndrome that is characterized by the development of bilateral vestibular schwannomas (BVSs) in almost all patients. This disease is caused by inactivating mutations of the neurofibromatosis type 2 (NF2) tumour-suppressor gene. BVSs result in hearing loss, tinnitus and balance dysfunction. The average age of onset is between 18 and 24 years. Patients may also suffer from schwannomas of other cranial and peripheral nerves, meningiomas, ependymomas, and rarely, astrocytomas. Although most of these tumours are not malignant, their anatomic location and multiplicity lead to high morbidity and mortality at a low age: the average age of death is 36 years. NF2-related schwannomatosis occurs in approximately 1 in 28,000 live births and the estimated prevalence in the general population is 1 in 50,000 without any known ethnic or racial bias. For known pathogenic mutations the penetrance is close to 100% (Asthagiri et al. 2009).

Mutational analysis of the NF2 gene has demonstrated causative mutations in ~70% of typical NF2-related schwannomatosis patients. The NF2 gene behaves as a typical tumour-suppressor gene, with first hits detectable in both constitutional and tumour specimens and second hits detectable only in tumours. Approximately 50% of NF2 mutation-positive patients inherit a germline mutation from an affected parent and the remaining half are sporadic cases due to de novo mutations. Large deletions or duplications affecting the NF2 gene account for 15-20% of all known NF2 mutations (Abo-Dalo et al. 2010; Halliday et al. 2017; Kluwe et al. 2005; Smith et al. 2016). A high level of mosaicism is observed in NF2-related schwannomatosis, which can complicate mutation detection. An estimated 45-60% of de novo cases are mosaic for NF2 mutations, which may result in subclinical symptoms and/or difficulties with mutation detection, resulting in a false negative diagnosis (Evans et al. 2020, Forde et al. 2024).

Mutations in NF2 are also frequently found in sporadic schwannomas and meningiomas (Lassaletta et al. 2013; Mohyuddin et al. 2002; Pathmanaban et al. 2017).

Regulatory status

SALSA MLPA Probemix P044 NF2 is CE-marked under the IVDR for in vitro diagnostic (IVD) use in Europe.

This assay is for research use only (RUO) in all other territories.

Product documentation

Version D1

Version C1

Other versions

Contact us for earlier versions.

Translations and Summary of Safety and Performance

Translations of the product description in selected European languages are available upon request. Please contact us or one of our local sales partners. Translations of the MLPA General Protocol in selected languages are available here.

The Summary of Safety and Performance (SSP) is also available upon request.

List prices

Product

Item no.
Description
Technology
Price
P044-025R
SALSA MLPA Probemix P044 NF2 – 25 rxn
MLPA
€ 296.00
P044-050R
SALSA MLPA Probemix P044 NF2 – 50 rxn
MLPA
€ 580.00
P044-100R
SALSA MLPA Probemix P044 NF2 – 100 rxn
MLPA
€ 1135.00

Required reagents

A general SALSA MLPA Reagent Kit is required for MLPA experiments (to be ordered separately).

Item no.
Description
Technology
Price
EK1-FAM
SALSA MLPA Reagent Kit – 100 rxn – FAM (6 vials)
MLPA MS-MLPA
€ 361.00
EK1-CY5
SALSA MLPA Reagent Kit – 100 rxn – Cy5 (6 vials)
MLPA MS-MLPA
€ 361.00
EK5-FAM
SALSA MLPA Reagent Kit – 500 rxn – FAM (5×6 vials)
MLPA MS-MLPA
€ 1658.00
EK5-CY5
SALSA MLPA Reagent Kit – 500 rxn – Cy5 (5×6 vials)
MLPA MS-MLPA
€ 1658.00
EK20-FAM
SALSA MLPA Reagent Kit – 2000 rxn – FAM (5×6 vials)
MLPA MS-MLPA
€ 6373.00

Other products

These optional accessories can be ordered separately.

Item no.
Description
Technology
Price
SMR05
SALSA FFPE Solution (SFS) – 50 rxn (10 ml)
MLPA MS-MLPA
€ 47.00

Price details & ordering

The prices above are list prices for direct orders from MRC Holland. Contact us for a quote that takes discounts and additional costs (such as shipping costs) into account. Different prices apply for orders through one of our sales partners; contact your local supplier for a quote.

More information about ordering & prices

Positive samples

Inclusion of a positive sample is usually not required, but can be useful for the analysis of your experiments. MRC Holland has very limited access to positive samples and cannot supply such samples. We recommend using positive samples from your own collection. Alternatively, you can use positive samples from an online biorepository, such as the Coriell Institute.

Current product version: D1

The commercially available positive samples below can be used with the current (D1) version of this product.

  • Coriell NA07106: Heterozygous duplication affecting all NF2 probes. The flanking probes are also affected.

Previous product version: C1

The commercially available positive samples below can be used with the C1 version of this product.

  • Coriell NA07106: Heterozygous duplication affecting all NF2 probes. The flanking probes are also affected.

Resources

General MLPA resources

MLPA education

Publications

Selected publications using P044 NF2

  • Chen H et al. (2018). Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. EBioMedicine. 36:252-65.
  • Evans DG et al. (2018). Schwannomatosis: a genetic and epidemiological study. J Neurol Neurosurg Psychiatry. 89:1215-9.
  • Evans DG et al. (2019). Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testing. Genet Med. 21:1525-33.
  • Evans DG et al. (2019). Familial unilateral vestibular schwannoma is rarely caused by inherited variants in the NF2 gene. Laryngoscope. 129:967-73.
  • Evans DG et al. (2020). Incidence of mosaicism in 1055 de novo NF2 cases: much higher than previous estimates with high utility of next-generation sequencing. Genet Med. 22:53-9.
  • Forde C et al. (2021). Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution. Neuro Oncol. 23:1113-24.
  • Forde C et al. (2024). NF2-related schwannomatosis and other schwannomatosis: an updated genetic and epidemiological study. J Med Genet. 61:856-60.
  • Kluwe L et al. (2005). Screening for large mutations of the NF2 gene. Genes Chromosomes Cancer. 42:384-91.
  • Pasmant E et al. (2018). Neurofibromatosis type 2 French cohort analysis using a comprehensive NF2 molecular diagnostic strategy. Neurochirurgie. 64:335-41.
  • Smith MJ et al. (2016). The Contribution of Whole Gene Deletions and Large Rearrangements to the Mutation Spectrum in Inherited Tumor Predisposing Syndromes. Hum Mutat. 37:250-6.

References

  • Abo-Dalo B et al. (2010). Large intragenic deletions of the NF2 gene: breakpoints and associated phenotypes. Genes Chromosomes Cancer. 49:171-5.
  • Asthagiri AR et al. (2009). Neurofibromatosis type 2. Lancet. 373:1974-86.
  • Evans DG et al. (2020). Incidence of mosaicism in 1055 de novo NF2 cases: much higher than previous estimates with high utility of next-generation sequencing. Genet Med. 22:53-9.
  • Evans DGR et al. (2007). Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. J Med Genet. 44:424-8.
  • Forde C et al. (2024). NF2-related schwannomatosis and other schwannomatosis: an updated genetic and epidemiological study. J Med Genet. 61:856-60.
  • Halliday D et al. (2017). Genetic Severity Score predicts clinical phenotype in NF2. J Med Genet. 54:657-64.
  • Kluwe L et al. (2005). Screening for large mutations of the NF2 gene. Genes Chromosomes Cancer. 42:384-91.
  • Lassaletta L et al. (2013). NF2 genetic alterations in sporadic vestibular schwannomas: clinical implications. Otol Neurotol. 34:1355-61.
  • Mohyuddin A et al. (2002). Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas. J Med Genet. 39:315-22.
  • Pathmanaban ON et al. (2017). Association of Genetic Predisposition With Solitary Schwannoma or Meningioma in Children and Young Adults. JAMA Neurol. 74:1123-9.
  • Smith MJ et al. (2016). The Contribution of Whole Gene Deletions and Large Rearrangements to the Mutation Spectrum in Inherited Tumor Predisposing Syndromes. Hum Mutat. 37:250-6.
This site uses cookies to help improve your online experience. Learn more
No, thank you accept

Sign in

Don't have an account? Create one

Forgot password?

Select Your Country

Choose your country to see the products for your location

CE2797

CE-marked products are for In Vitro Diagnostic (IVD) use only in EU (candidate) member states and members of the European Free Trade Association (EFTA), and the UK.

Improvements

Twelve reference probes were replaced.